Over the last decade, FDA commissioners have generally steered clear from the nitty-gritty of drug applications, the opinions of drug review staff, or trying to bend laws that prohibit the agency from attempting to influence …
Eisai plots label expansion for subcutaneous Leqembi, details early launch progress
Eisai said it’s planning a rolling FDA submission next month to expand the use of its Biogen-partnered subcutaneous Alzheimer’s treatment, the latest effort to stoke



